Investors in the biotechnology sector often follow trends and popular fads when funding startups, much like investors in other industries. However, the key to true success lies in tackling important but neglected challenges. Instead of focusing on mainstream areas, it is essential to champion solutions to tough, high-value problems that few others are addressing.
One such area is atherosclerosis, where current treatments have fallen short in reversing plaque growth. Similarly, a universal cancer therapy that targets common mechanisms across various types of cancer could revolutionize treatment. Additionally, there is a pressing need for more effective antiviral therapies and means to selectively suppress excessive inflammation associated with aging.
Moreover, there is a significant gap in the infrastructure for conducting faster, cheaper, and responsible clinical trials. Exploring alternative options to the traditional FDA and EMA systems could pave the way for innovative and cost-effective approaches to therapy development. Startups like Cyclarity Therapeutics and Repair Biotechnologies are leading the way, but there is ample opportunity for others to make a mark in the rejuvenation biotechnology space.
